March 8, 2018 / 11:18 AM / 6 months ago

BRIEF-VBL Therapeutics Announces Top-Line Results From Pivotal Phase 3 Globe Study In Patients With Recurrent Glioblastoma

March 8 (Reuters) - Vascular Biogenics Ltd:

* VBL THERAPEUTICS ANNOUNCES TOP-LINE RESULTS FROM PIVOTAL PHASE 3 GLOBE STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

* VASCULAR BIOGENICS LTD - ‍STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​

* VASCULAR BIOGENICS LTD - PHASE 3 GLOBE STUDY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF OVERALL SURVIVAL​

* VASCULAR BIOGENICS LTD - ‍BELIEVE THAT VB-111 MAY STILL HOLD PROMISE FOR OTHER INDICATIONS CO CURRENTLY OR MAY STUDY IN FUTURE​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below